Post by zieg on Sept 18, 2014 14:49:33 GMT -5
doctor.stockpicker • 19 hours ago Flag43 users liked this posts users disliked this posts 2 Reply Mr. Mann's interview from a physician's viewpoint
I read Mr Mann's interview last night and was pleased when he stated that Afrezza should be dosed a few minutes after the beginning of a meal. Previously, I had came to the same conclusion as I was studying the pharmacodynmacs of Afrezza. Reading those comments along with the statements about the upcoming larger dosed cartridges lead me to make this definitive statement and prediction. Afrezza will be the standard of care for mealtime insulin use in all type 1 diabetics and will be used very early in all type 2 diabetics in combination with metformin. My reasoning is this. In type 1 diabetics, the disease process is a lack of beta cells that produce insulin. Afrezza more closely (especially dosed as Mr. Mann discussed) replicates any prandial insulin that is currently available. In type 2 diabetics, it is now known that there is two defects. The one that was first discovered was that diabetics are resistant to the insulin produced by the pancreas. More recently discovered is that diabetics have a defect in first phase insulin response and Afrezza is the drug that most replicates this response. I am challenging anyone to post the medical reasoning that would contradict these statements. I have owned Mannkind for a long time and I am more convinced that ever that this is future for all diabetics.
I read Mr Mann's interview last night and was pleased when he stated that Afrezza should be dosed a few minutes after the beginning of a meal. Previously, I had came to the same conclusion as I was studying the pharmacodynmacs of Afrezza. Reading those comments along with the statements about the upcoming larger dosed cartridges lead me to make this definitive statement and prediction. Afrezza will be the standard of care for mealtime insulin use in all type 1 diabetics and will be used very early in all type 2 diabetics in combination with metformin. My reasoning is this. In type 1 diabetics, the disease process is a lack of beta cells that produce insulin. Afrezza more closely (especially dosed as Mr. Mann discussed) replicates any prandial insulin that is currently available. In type 2 diabetics, it is now known that there is two defects. The one that was first discovered was that diabetics are resistant to the insulin produced by the pancreas. More recently discovered is that diabetics have a defect in first phase insulin response and Afrezza is the drug that most replicates this response. I am challenging anyone to post the medical reasoning that would contradict these statements. I have owned Mannkind for a long time and I am more convinced that ever that this is future for all diabetics.
